Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL647038 | 0.84 | TSHR (0.42) | — | |
| SCHEMBL760689 | 0.84 | CA12 (0.39) | — | |
| SCHEMBL27977711 | 0.82 | CA12 (0.38) | — | |
| SCHEMBL28194644 | 0.82 | CA12 (0.38) | — | |
| SCHEMBL31412866 | 0.77 | CA12 (0.50) | — | |
| SCHEMBL30918965 | 0.77 | VEGFA (0.34) | VEGFA | |
| SCHEMBL31322177 | 0.77 | ERN1 (0.31) | — | |
| SCHEMBL28083641 | 0.77 | CA12 (0.50) | — | |
| SCHEMBL30078202 | 0.75 | ALDH1A1 (0.31) | — | |
| SCHEMBL31300184 | 0.75 | RAPGEF4 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497392-B2 | EP300/CBP inhibitor | HINOVA PHARMACEUTICALS INC. (CN) | 2025-12-16 | — | — | US | disclosed |
| CN-109422674-B | Organic molecules, in particular for optoelectronic devices | 三星显示有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20230027088-A1 | EP300/CBP INHIBITOR | HINOVA PHARMACEUTICALS INC. (CN) | 2023-01-26 | — | — | US | disclosed |
| EP-4043458-A1 | EP300/CBP INHIBITOR | Hinova Pharmaceuticals Inc. (CN) | 2022-08-17 | — | — | EP | disclosed |
| US-8409673-B2 | Chlorobenzene derivative, optically isotropic liquid crystal medium, and optical device | JNC CORPORATION (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20120099039-A1 | CHLOROBENZENE DERIVATIVE, OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM, AND OPTICAL DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-04-26 | — | — | US | disclosed |
| EP-2433923-A1 | CHLOROBENZENE DERIVATIVE, OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM, AND OPTICAL ELEMENT | JNC Corporation (JP) | 2012-03-28 | — | — | EP | disclosed |
| EP-2323978-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12497392-B2 | EP300/CBP inhibitor | EP300, MLLT1, CREBBP | EPAS1 718/4885VEGFA 4857/4885 |
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | EPAS1 3701/4885VEGFA 3111/4885 |
| US-20230027088-A1 | EP300/CBP INHIBITOR | EP300, MLLT1, CREBBP | EPAS1 718/4885VEGFA 4857/4885 |
| US-20120099039-A1 | CHLOROBENZENE DERIVATIVE, OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM, AND OPTICAL DEVICE | CRYAB, CYBA, CCNB1 | EPAS1 4209/4885VEGFA 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.